相关实验视频

Updated: May 25, 2025

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

针对TRPC-5通道抑制来改善勃起功能障碍的阴茎血管功能

Mariam El Assar^1,2,3, Borja García-Gómez⁴, José M La Fuente⁵

¹Fundación para la Investigación Biomédica del Hospital de Getafe, 28905 Getafe, Spain.

International journal of molecular sciences

|February 26, 2025

概括

用AC1903准TRPC5通道改善了老年老鼠和勃起功能障碍 (ED) 患者的阴茎血管功能. 这种TRPC5抑制增强了PDE5抑制剂的有效性,为ED提供了潜在的治疗策略.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
血管生物学血管生物学
药理学药理学是指药理学的学科.

背景情况:

规范性短暂受体潜力 (TRPC) 通道对于平衡至关重要,影响阴茎血管收缩性和勃起功能障碍 (ED).
TRPC通道失调与ED的病理生理学有关.

研究的目的:

研究TRPC5抑制对老老鼠和ED患者阴茎血管内皮功能的影响.
评估TRPC5抑制对固酶5型 (PDE5) 抑制剂的疗效的影响.

主要方法:

评估了TRPC抑制剂诱导的老老鼠和人类阴茎组织 (阴茎体 - HCC,阴茎抗性动脉 - HPRAs) 的阴茎体 (RCC) 的放松,这些放松来自ED患者和器官捐赠者.
评估了TRPC5抑制剂AC1903以及TRPC3和TRPC4抑制剂对血管放松的影响.
通过AC1903在人类阴茎组织中确定塔达拉菲尔 (一种PDE5抑制剂) 放松的潜在作用.

主要成果:

与TRPC3和TRPC4抑制剂相比,TRPC5抑制剂AC1903在ED患者的老年RCC,HCC和HPRA中表现出优异的放松效应.
在老鼠RCC中,AC1903增强了内皮和神经元放松,在ED患者中改善了人类HCC和HPRA的内皮依赖放松.
在ED患者的人体阴茎组织中,AC1903增强了tadalafil诱导的放松作用.

结论:

在老老鼠和ED患者中,TRPC5抑制显著改善阴茎血管功能.
TRPC5抑制是ED治疗的有希望的治疗标,在与PDE5抑制剂相结合时,可能会提高结果.

关键词:

TRPC5 TRPC5 需要一个人.衰老的衰老衰老的衰老正规的短暂受体潜力 (TRPC) 道.内皮质功能障碍内皮质功能障碍这是勃起功能障碍.人类的身体洞穴总和.人类阴茎动脉的人类阴茎动脉神经生理放松神经生理放松

更多相关视频

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Nitric Oxide Signaling Pathway

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...